174 related articles for article (PubMed ID: 27185207)
1. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
[TBL] [Abstract][Full Text] [Related]
2. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
Patnaik MM; Tefferi A
Blood Cancer J; 2016 Feb; 6(2):e393. PubMed ID: 26849014
[TBL] [Abstract][Full Text] [Related]
4. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
[TBL] [Abstract][Full Text] [Related]
6. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.
Gagelmann N; Badbaran A; Beelen DW; Salit RB; Stölzel F; Rautenberg C; Becker H; Radujkovic A; Panagiota V; Bogdanov R; Christopeit M; Park Y; Nibourel O; Luft T; Koldehoff M; Corsten M; Heuser M; Finke J; Kobbe G; Platzbecker U; Robin M; Scott BL; Kröger N
Blood Adv; 2021 Mar; 5(6):1760-1769. PubMed ID: 33755092
[TBL] [Abstract][Full Text] [Related]
7. Germline
Bochicchio MT; Micucci G; Asioli S; Ghetti M; Simonetti G; Lucchesi A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003211
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.
Bastie JN; Aucagne R; Droin N; Solary E; Delva L
Cell Mol Life Sci; 2012 Sep; 69(17):2853-61. PubMed ID: 22415325
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
[TBL] [Abstract][Full Text] [Related]
10. Sex-associated differences in genomic profile of chronic myelomonocytic leukemia involving differential representation of SRSF2 gene mutation.
Calvo X; Roman-Bravo D; Garcia-Gisbert N; Fernández-Rodríguez C; Rial-Villavecchia A; Garcia-Avila S; López-Cadenas F; Salido M; Ferrer Del Álamo A; Arenillas L
Int J Lab Hematol; 2023 Dec; 45(6):1011-1015. PubMed ID: 37536950
[No Abstract] [Full Text] [Related]
11. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2018 Jun; 93(6):824-840. PubMed ID: 29878489
[TBL] [Abstract][Full Text] [Related]
13. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
14. Current management of patients with chronic myelomonocytic leukemia.
Alfonso A; Montalban-Bravo G; Garcia-Manero G
Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.
Dinmohamed AG; van Norden Y; van de Loosdrecht AA; Jongen-Lavrencic M
Leukemia; 2016 Aug; 30(8):1795-6. PubMed ID: 27198054
[No Abstract] [Full Text] [Related]
16. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Thépot S; Ben Abdelali R; Chevret S; Renneville A; Beyne-Rauzy O; Prébet T; Park S; Stamatoullas A; Guerci-Bresler A; Cheze S; Tertian G; Choufi B; Legros L; Bastié JN; Delaunay J; Chaury MP; Sanhes L; Wattel E; Dreyfus F; Vey N; Chermat F; Preudhomme C; Fenaux P; Gardin C;
Haematologica; 2016 Aug; 101(8):918-25. PubMed ID: 27229713
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Döhner H; Estey E; Grimwade D; Amadori S; Appelbaum FR; Büchner T; Dombret H; Ebert BL; Fenaux P; Larson RA; Levine RL; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz M; Sierra J; Tallman MS; Tien HF; Wei AH; Löwenberg B; Bloomfield CD
Blood; 2017 Jan; 129(4):424-447. PubMed ID: 27895058
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
